Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/16/23
End: 06/01/25
Due: 06/01/26
Phase: N/A
Priority: Normal
Start: 05/01/24
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 05/30/23
End: 05/30/25
Due: 05/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency | NCT06205758 | Yi Han | user2@example.com | None | 2023-11-16 | 2025-06-01 | 2026-06-01 | - | - | 2025-07-14 |
| Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in Patients With Moderate to Severe Renal Insufficiency | NCT06431789 | Yi Han | user2@example.com | None | 2024-05-01 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |
| Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure | NCT05913271 | Yi Han | user2@example.com | None | 2023-05-30 | 2025-05-30 | 2026-05-30 | - | - | 2025-07-14 |